PT  - JOURNAL ARTICLE
AU  - Anna Ostropolets
AU  - Xintong Li
AU  - Rupa Makadia
AU  - Gowtham Rao
AU  - Peter R. Rijnbeek
AU  - Talita Duarte-Salles
AU  - Anthony G. Sena
AU  - Azza Shaoibi
AU  - Marc A. Suchard
AU  - Patrick B. Ryan
AU  - Daniel Prieto-Alhambra
AU  - George Hripcsak
TI  - Empirical evaluation of the sensitivity of background incidence rate characterization for adverse events across an international observational data network
AID  - 10.1101/2021.06.27.21258701
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.27.21258701
4099  - http://medrxiv.org/content/early/2021/07/02/2021.06.27.21258701.short
4100  - http://medrxiv.org/content/early/2021/07/02/2021.06.27.21258701.full
AB  - Background incidence rates are routinely used in safety studies to evaluate the association of an exposure and an outcome. Systematic research on the sensitivity of background rates to the choice of the study parameters is lacking. We used 12 electronic health record and administrative claims data sources to calculate incidence rates of 15 adverse events. We examined the influence of age, race, sex, database, time-at-risk start (anchoring) event and duration, season and year, prior observation and clean window. For binary comparisons, we calculated incidence rate ratios and performed random-effect model meta-analysis. Background rates were highly sensitive to demographic characteristics of the population, especially age, with rates varying up to a factor of 1,000 across age groups. Rates varied by up to a factor of 100 by database. Incidence rates were highly influenced by the choice of anchoring (e.g., health visit, vaccination, or arbitrary date) for the time-at-risk start, especially at short times at risk, and less influenced by secular or seasonal trends. Therefore, comparing background to observed rates requires appropriate adjustment, and results should be interpreted in the context of design choices.Competing Interest StatementGH and AO receive funding from the US National Institutes of Health (NIH) and the US Food and Drug Administration. DPA research group has received research grants from the European Medicines Agency; the Innovative Medicines Initiative; Amgen, Chiesi, and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, Astra Zeneca, and UCB Biopharma. PR works for a research group that receives/received unconditional research grants from Yamanouchi, Pfizer-Boehringer Ingelheim, Novartis, GSK, Amgen, and Chiesi, none of which relates to the content of this paper. PBR, RM, AS, GR, and AGS are employees of Janssen Research and Development and shareholders in Johnson and Johnson. MAS receives grants and contracts from the FDA and the US Department of Veterans Affairs within the scope of this research, and grants and contracts from NIH, IQVIA, and Private Health Management outside the scope of this research.Funding StatementUS National Library of Medicine (R01 LM006910), US Food and Drug Administration CBER BEST Initiative (75F40120D00039), UK National Institute of Health Research (NIHR), European Medicines Agency, Innovative Medicines Initiative 2 (806968).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol for this research was approved by the Columbia University Institutional Review Board (AAAO7805), the Independent Scientific Advisory Committee (ISAC) for MHRA Database Research (20_000211), the IDIAPJGol Clinical Research Ethics Committee (project code: 21/007-PCV), the IPCI governance board (application number 3/2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPatient-level data cannot be shared without approval from data custodians due to local information governance and data protection regulations. Aggregated data, analytical code, and detailed definitions of algorithms for identifying the events are available in a GitHub repository (https://github.com/ohdsi-studies/Covid19VaccineAesiIncidenceCharacterization). https://github.com/ohdsi-studies/Covid19VaccineAesiIncidenceCharacterization